

Emily Turner, PhD



Emily Turner, Ph.D., is the Executive Director of the Huntington's Disease Regulatory Science Consortium (HD-RSC) at C-Path. She received her undergraduate degree in psychology and art history from Northwestern University in Evanston, IL and earned a Ph.D. in neuroscience from Vanderbilt University in Nashville, TN, where she studied systems neuroscience in a non-human primate laboratory. She completed her postdoctoral training at the ASU-Banner Neurodegenerative Disease Research Center in Tempe, AZ. Dr. Turner has served as an ad hoc reviewer in peer-reviewed scientific journals, and enjoys serving as a professional mentor for women in STEM careers.

Her specific areas of technical expertise include neuroanatomy, neuropathology and animal models of neurodegenerative diseases. While in academia she focused her research on drug discovery for Alzheimer's disease and other related neurodegenerative diseases and has numerous publications in the neuroscience area. In her current role, she leads the HD-RSC which brings together diverse stakeholders in the HD community to define and address regulatory needs to accelerate HD therapeutic development. Dr. Turner is passionate about bringing much needed therapeutics to patients suffering from rare diseases, and is honored to lead the HD-RSC team at C-Path.